See more
Is Henry Schein stock a Buy, Sell or Hold?
Henry Schein stock has received a consensus rating of buy. The average rating score is and is based on 4 buy ratings, 0 hold ratings, and 2 sell ra...
What was the 52-week low for Henry Schein stock?
The low in the last 52 weeks of Henry Schein stock was 70.25. According to the current price, Henry Schein is 115.91% away from the 52-week low.
What was the 52-week high for Henry Schein stock?
The high in the last 52 weeks of Henry Schein stock was 92.68. According to the current price, Henry Schein is 87.86% away from the 52-week high.
What are analysts forecasts for Henry Schein stock?
The 6 analysts offering price forecasts for Henry Schein have a median target of 83.50, with a high estimate of 100.00 and a low estimate of 67.00....
Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
When will Henry Schein buy back his stock?
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
When will Henry Schein release its earnings?
How will Henry Schein's stock buyback program work? Henry Schein declared that its Board of Directors has approved a share repurchase program on Thursday, May 13th 2021, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor.
How much does Henry Schein make?
Henry Schein is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021. View our earnings forecast for Henry Schein.
When did Henry Schein split?
Henry Schein has a market capitalization of $10.88 billion and generates $10.12 billion in revenue each year. The company earns $403.79 million in net income (profit) each year or $2.97 on an earnings per share basis.
When is Henry Schein's earnings conference call?
Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.
Nasdaq Global Select
Henry Schein will be holding an earnings conference call on Tuesday, August 3rd at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.
Environmental, Social, and Governance Rating
The Company is a distributor of healthcare products & services primarily to office-based healthcare practitioners in the combined North American & European markets. Conducts business through two segments; healthcare distribution & technology.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
A spinoff threw financial data sites for a loop today -- but not to worry. We'll clarify things for you
The Company is a distributor of healthcare products & services primarily to office-based healthcare practitioners in the combined North American & European markets. Conducts business through two segments; healthcare distribution & technology.
What happened
I like things that go "boom." Sonic or otherwise, that means I tend to gravitate towards defense and aerospace stocks. But to tell the truth, over the course of a dozen years writing for The Motley Fool, I have covered -- and continue to cover -- everything from retailers to consumer goods stocks, and from tech to banks to insurers as well.
So what
Shares of medical supplies distributor Henry Schein ( NASDAQ:HSIC) are down 26.5% as of 11:35 a.m. EST -- or are they only really down about 6%? The answer depends on how you look at it.
Now what
Technically, since Henry Schein shares closed at $79.69 yesterday, but cost only $58.55 today, well, that's a 26.5% drop. But here's the thing: On Jan.
Signals & Forecast
Henry Schein says it received $1.1 billion in "tax-free proceeds" from the spinoff and remerger of its animal health business, funds that will be used to pay off about half of the company's $2.2 billion debt load.
Support, Risk & Stop-loss
The Henry Schein stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Is Henry Schein stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $77.86 and $74.77. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Henry Schein finds support just below today's level at $77.86.
Insiders are neutral buying more shares than they are selling in Henry Schein
Henry Schein holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Henry Schein
In the last 100 trades there were 520.29 thousand shares bought and 329.9 thousand shares sold. The last trade was done 3 days ago by Mlotek Mark E who sold 24.08 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates in two segments, Health Care Distribution; and Technology and Value-Added Services.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.